ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Hidradenitis Suppurativa (HS)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 79 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Oruka Therapeutics, Inc.

Last updated on ClinicalTrials.gov

September 24, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites